☆ 4.8 Article

Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study

Lan-Ping Xu et al.

Summary: In recent years, haploidentical stem cell transplantation has made significant progress in treating severe aplastic anemia. Through a multicenter prospective study, it was found that salvage transplantation with haploidentical donors can achieve favorable long-term outcomes, including high survival rates and quality of life recovery.

SCIENCE BULLETIN (2022)

Add to Collection

Article Oncology

Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less

Atsushi Marumo et al.

Summary: Cyclophosphamide (CY)-induced cardiotoxicity is rare but potentially lethal. Lowering the dose of CY can reduce the risk of heart failure, but even doses below 120 mg/kg can still cause cardiotoxicity.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Letter Biophysics

Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia

Lan-Ping Xu et al.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Hematology

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial

Amy E. DeZern et al.

Summary: Haploidentical bone marrow transplantation is effective in treating relapsed or refractory severe aplastic anaemia patients with high overall survival rates at 1 year, which can broaden access to bone marrow transplantation and be considered as a standard salvage treatment for severe aplastic anaemia in clinical practice. High cell doses from bone marrow harvests are crucial for the success of this approach.

LANCET HAEMATOLOGY (2022)

Add to Collection

Article Oncology

Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation

Remy Dulery et al.

Summary: This study compared clinical outcomes between patients who received post-transplant cydophosphamide (PT-Cy) and patients who did not, finding a higher incidence of early cardiac events in patients who received PT-Cy.

JACC: CARDIOONCOLOGY (2021)

Add to Collection

Article Surgery

The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia

Zheng-Li Xu et al.

Summary: The study showed that the incidence of MC was significantly lower in HID transplants, and MC was associated with lower levels of CD3 + cells, lower rates of II-IV aGvHD, higher rates of secondary graft rejection, and poorer overall survival.

CLINICAL TRANSPLANTATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA

Yingling Zu et al.

Summary: The use of posttransplant cyclophosphamide (PTCy) along with cotransplantation of peripheral blood stem cells (PBSCs) and human umbilical cord-derived mesenchymal stem cells (UC-MSCs) is an effective and safe treatment strategy for patients with severe aplastic anemia (SAA).

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Hematology

Optimizing outcomes for haploidentical hematopoietic stem cell transplantation in severe aplastic anemia with intensive GVHD prophylaxis: a review of current findings

Zheng-Li Xu et al.

Summary: Allogeneic hematopoietic stem cell transplantation has led to improved disease-free survival rates in severe aplastic anemia. Haploidentical transplantation was previously not recommended due to high incidences of graft-versus-host disease and graft failures. However, with intensive prophylaxis strategies, outcomes with haploidentical transplantation for severe aplastic anemia have gradually improved.

EXPERT REVIEW OF HEMATOLOGY (2021)

Add to Collection

Article Immunology

Haploidentical Hematopoietic Cell Transplantation Using Post-transplant Cyclophosphamide for Children with Non-malignant Diseases

Hasan Hashem et al.

Summary: Haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) is a valuable curative option for children with non-malignant diseases when an HLA-matched donor is not available. Younger age at HCT (<4 years) and primary immunodeficiency are significantly associated with better survival outcomes. Early diagnosis, timely treatment, and referral can further improve outcomes for these children.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Haploidentical Peripheral Stem Cell Transplantation for Young Patients with Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide and Methotrexate

Kaitai Yang et al.

Summary: The study investigated a novel approach to HSCT, haploidentical peripheral blood stem cell transplantation, for patients with SAA who lack HLA-identical siblings or matched unrelated donors. The results showed promising outcomes with low rates of graft-versus-host disease, indicating the potential for safely expanding the donor pool for young patients with severe aplastic anemia.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Hematology

Haploidentical Transplantation with Modified Post-transplantation Cyclophosphamide for Patients with Primary Aplastic Anemia: A Multicenter Experience

Yun Li et al.

Summary: Haploidentical transplantation with modified post-transplantation cyclophosphamide (PTCY) has shown promising results for aplastic anemia patients, leading to prolonged survival and reduced complications. The conditioning regimen consisting of various medications was effective in preventing graft versus host disease (GVHD) post-transplantation. Overall, the study demonstrated high rates of successful engraftment and survival among patients undergoing this treatment strategy.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Letter Biology

Haploidentical hematopoietic cell transplantation for severe acquired aplastic anemia: a case-control study of post-transplant cyclophosphamide included regimen vs. anti-thymocyte globulin & colony-stimulating factor-based regimen

Lanping Xu et al.

SCIENCE CHINA-LIFE SCIENCES (2020)

Add to Collection

Article Biophysics

Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party

Pedro H. Prata et al.

BONE MARROW TRANSPLANTATION (2020)

Add to Collection

Article Biophysics

Impact of ABO incompatibility on outcomes after haploidentical hematopoietic stem cell transplantation for severe aplastic anemia

Yan-Ru Ma et al.

BONE MARROW TRANSPLANTATION (2020)

Add to Collection

Article Surgery

Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: A retrospective multicenter cohort study

Yuan-Yuan Zhang et al.

CLINICAL TRANSPLANTATION (2020)

Add to Collection

Article Hematology

A Case Series of Post-Transplantation Cyclophosphamide in Unrelated Donor Hematopoietic Cell Transplantation for Aplastic Anemia

Leonardo Javier Arcuri et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Article Hematology

Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide

Amy E. DeZern et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

Yu Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection

Article Oncology

Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study

Lan-Ping Xu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)

Add to Collection

Review Immunology

Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding

Natalia S. Nunes et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Article Hematology

Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

Yue Lu et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)

Add to Collection

Article Hematology

Graft failure after allogeneic hematopoietic stem cell transplantation

Zehra Narli Ozdemir et al.

TRANSFUSION AND APHERESIS SCIENCE (2018)

Add to Collection

Review Medicine, General & Internal

Aplastic Anemia

Neal S. Young

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant

Lan-Ping Xu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

F. M. Marty et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes

Yu Wang et al.

ONCOIMMUNOLOGY (2017)

Add to Collection

Article Hematology

Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia

Amy E. DeZern et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)

Add to Collection

Article Hematology

How I treat acquired aplastic anemia

Andrea Bacigalupo

BLOOD (2017)

Add to Collection

Article Hematology

Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders

Orly R. Klein et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)

Add to Collection

Article Hematology

Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study

Lan-Ping Xu et al.

BRITISH JOURNAL OF HAEMATOLOGY (2016)

Add to Collection

Review Immunology

Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations

Taiga Nishihori et al.

IMMUNOTHERAPY (2016)

Add to Collection

Article Hematology

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

Madan H. Jagasia et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)

Add to Collection

Article Biophysics

Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study

I. Esteves et al.

BONE MARROW TRANSPLANTATION (2015)

Add to Collection

Article Hematology

Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia

Jennifer Clay et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

Add to Collection

Article Biophysics

A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia

L. P. Xu et al.

BONE MARROW TRANSPLANTATION (2012)

Add to Collection

Letter Biophysics

Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia

A. E. DeZern et al.

BONE MARROW TRANSPLANTATION (2011)

Add to Collection

Article Hematology

Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation

DP Lu et al.

BLOOD (2006)

Add to Collection

Article Biophysics

Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia

JR Passweg et al.

BONE MARROW TRANSPLANTATION (2006)

Add to Collection

Review Medicine, General & Internal

Aplastic anaemia

RA Brodsky et al.

LANCET (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.